Výsledky vyhledávání - "Phillip McEwan"

Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model

Autor: Denis Getsios, Ipek Özer Stillman, Phillip McEwan, Aurelie Danel, J. Jaime Caro

Publikováno v: Journal of Medical Economics. 10:239-254

SummaryRimonabant, the first selective CB-1 receptor blocker, is expected to reduce cardiometabolic risk substantially. This study assesses the economics of such treatment in patients at elevated cardiometabolic risk.A Markov model was developed usin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a422b3b2604643224102a062edc20896
https://doi.org/10.3111/13696990701438629

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání